Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair

Behzad N. Oskouei, Guillaume Lamirault, Chacko Joseph, Adriana V. Treuer, Stephanie Landa, Jose Da Silva, Konstantinos Hatzistergos, Marc Dauer, Wayne E Balkan, Ian McNiece, Joshua Hare

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Whereas cardiac-derived c-kit+ stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (MSCs) are undergoing clinical trials testing safety and efficacy as a cell-based therapy, the relative therapeutic and biologic efficacy of these two cell types is unknown. We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation. The myocardial infarction-induced enlargement in left ventricular chamber dimensions was ameliorated by CSCs (p <.05 for diastolic and systolic volumes), as was the decline in ejection fraction (EF; p <.05). Whereas 1 × 106 MSCs partially ameliorated ventricular remodeling and improved EF to a similar degree as CSCs, 36,000 MSCs did not influence chamber architecture or function. All cell therapies improved myocardial contractility, but CSCs preferentially reduced scar size and reduced vascular afterload. Engraftment and trilineage differentiation was substantially greater with CSCs than with MSCs. Adult-cultured c-kit+ CSCs were less effective than fetal, but were still more potent than high-dose MSCs. These data demonstrate enhanced CSC engraftment, differentiation, and improved cardiac remodeling and function in ischemic heart failure. MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.

Original languageEnglish
Pages (from-to)116-124
Number of pages9
JournalStem cells translational medicine
Volume1
Issue number2
DOIs
StatePublished - Dec 1 2012

Fingerprint

Mesenchymal Stromal Cells
Stem Cells
Bone Marrow
Cell- and Tissue-Based Therapy
Severe Combined Immunodeficiency
Adult Stem Cells
Ventricular Remodeling
Cicatrix
Ligation
Blood Vessels
Cell Differentiation
Anatomy
Coronary Vessels
Heart Failure
Phosphates
Myocardial Infarction
Clinical Trials
Safety
Injections

Keywords

  • c-kit
  • Cardiac
  • Mesenchymal stem cells
  • Myocardial infarction
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. / Oskouei, Behzad N.; Lamirault, Guillaume; Joseph, Chacko; Treuer, Adriana V.; Landa, Stephanie; Da Silva, Jose; Hatzistergos, Konstantinos; Dauer, Marc; Balkan, Wayne E; McNiece, Ian; Hare, Joshua.

In: Stem cells translational medicine, Vol. 1, No. 2, 01.12.2012, p. 116-124.

Research output: Contribution to journalArticle

Oskouei, BN, Lamirault, G, Joseph, C, Treuer, AV, Landa, S, Da Silva, J, Hatzistergos, K, Dauer, M, Balkan, WE, McNiece, I & Hare, J 2012, 'Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair', Stem cells translational medicine, vol. 1, no. 2, pp. 116-124. https://doi.org/10.5966/sctm.2011-0015
Oskouei, Behzad N. ; Lamirault, Guillaume ; Joseph, Chacko ; Treuer, Adriana V. ; Landa, Stephanie ; Da Silva, Jose ; Hatzistergos, Konstantinos ; Dauer, Marc ; Balkan, Wayne E ; McNiece, Ian ; Hare, Joshua. / Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. In: Stem cells translational medicine. 2012 ; Vol. 1, No. 2. pp. 116-124.
@article{5f8092661e6b4f0bad0f648569cbb5d9,
title = "Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair",
abstract = "Whereas cardiac-derived c-kit+ stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (MSCs) are undergoing clinical trials testing safety and efficacy as a cell-based therapy, the relative therapeutic and biologic efficacy of these two cell types is unknown. We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation. The myocardial infarction-induced enlargement in left ventricular chamber dimensions was ameliorated by CSCs (p <.05 for diastolic and systolic volumes), as was the decline in ejection fraction (EF; p <.05). Whereas 1 × 106 MSCs partially ameliorated ventricular remodeling and improved EF to a similar degree as CSCs, 36,000 MSCs did not influence chamber architecture or function. All cell therapies improved myocardial contractility, but CSCs preferentially reduced scar size and reduced vascular afterload. Engraftment and trilineage differentiation was substantially greater with CSCs than with MSCs. Adult-cultured c-kit+ CSCs were less effective than fetal, but were still more potent than high-dose MSCs. These data demonstrate enhanced CSC engraftment, differentiation, and improved cardiac remodeling and function in ischemic heart failure. MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.",
keywords = "c-kit, Cardiac, Mesenchymal stem cells, Myocardial infarction, Ventricular remodeling",
author = "Oskouei, {Behzad N.} and Guillaume Lamirault and Chacko Joseph and Treuer, {Adriana V.} and Stephanie Landa and {Da Silva}, Jose and Konstantinos Hatzistergos and Marc Dauer and Balkan, {Wayne E} and Ian McNiece and Joshua Hare",
year = "2012",
month = "12",
day = "1",
doi = "10.5966/sctm.2011-0015",
language = "English",
volume = "1",
pages = "116--124",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair

AU - Oskouei, Behzad N.

AU - Lamirault, Guillaume

AU - Joseph, Chacko

AU - Treuer, Adriana V.

AU - Landa, Stephanie

AU - Da Silva, Jose

AU - Hatzistergos, Konstantinos

AU - Dauer, Marc

AU - Balkan, Wayne E

AU - McNiece, Ian

AU - Hare, Joshua

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Whereas cardiac-derived c-kit+ stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (MSCs) are undergoing clinical trials testing safety and efficacy as a cell-based therapy, the relative therapeutic and biologic efficacy of these two cell types is unknown. We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation. The myocardial infarction-induced enlargement in left ventricular chamber dimensions was ameliorated by CSCs (p <.05 for diastolic and systolic volumes), as was the decline in ejection fraction (EF; p <.05). Whereas 1 × 106 MSCs partially ameliorated ventricular remodeling and improved EF to a similar degree as CSCs, 36,000 MSCs did not influence chamber architecture or function. All cell therapies improved myocardial contractility, but CSCs preferentially reduced scar size and reduced vascular afterload. Engraftment and trilineage differentiation was substantially greater with CSCs than with MSCs. Adult-cultured c-kit+ CSCs were less effective than fetal, but were still more potent than high-dose MSCs. These data demonstrate enhanced CSC engraftment, differentiation, and improved cardiac remodeling and function in ischemic heart failure. MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.

AB - Whereas cardiac-derived c-kit+ stem cells (CSCs) and bone marrow-derived mesenchymal stem cells (MSCs) are undergoing clinical trials testing safety and efficacy as a cell-based therapy, the relative therapeutic and biologic efficacy of these two cell types is unknown. We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation. The myocardial infarction-induced enlargement in left ventricular chamber dimensions was ameliorated by CSCs (p <.05 for diastolic and systolic volumes), as was the decline in ejection fraction (EF; p <.05). Whereas 1 × 106 MSCs partially ameliorated ventricular remodeling and improved EF to a similar degree as CSCs, 36,000 MSCs did not influence chamber architecture or function. All cell therapies improved myocardial contractility, but CSCs preferentially reduced scar size and reduced vascular afterload. Engraftment and trilineage differentiation was substantially greater with CSCs than with MSCs. Adult-cultured c-kit+ CSCs were less effective than fetal, but were still more potent than high-dose MSCs. These data demonstrate enhanced CSC engraftment, differentiation, and improved cardiac remodeling and function in ischemic heart failure. MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.

KW - c-kit

KW - Cardiac

KW - Mesenchymal stem cells

KW - Myocardial infarction

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=84871293889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871293889&partnerID=8YFLogxK

U2 - 10.5966/sctm.2011-0015

DO - 10.5966/sctm.2011-0015

M3 - Article

C2 - 23197758

AN - SCOPUS:84871293889

VL - 1

SP - 116

EP - 124

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 2

ER -